August 2020

A study determines the prevalence of mutations in two polymerases in patients with hereditary cancer

A team from the IDIBELL-ICO Hereditary Cancer group has studied more than 2,800 patients with a possible hereditary cancer to determine the frequency of pathogenic mutations in the corrective region of two polymerases.
Identifying these mutations can facilitate the early diagnosis and the personalized treatment of these patients.

Scroll to Top